Background: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU. To reduce neurotoxicity, whole-brain irradiation was reserved for patients not responding to chemotherapy.
introduction Primary central nervous system lymphoma (PCNSL) patients have a dismal prognosis despite initial response to steroids and whole-brain radiotherapy (WBRT) [1, 2] . Addition of highdose methotrexate (MTX) to WBRT has improved the prognosis of patients with PCNSL, resulting in median survival rates of up to 60 months. However, most patients eventually relapse [3] [4] [5] . MTX-based, multiagent chemotherapy regimens without WBRT can result in 5-year overall survival (OS) rates of up to 75% [6] [7] [8] [9] [10] . Recently, we and others reported that high-dose chemotherapy with autologous stem-cell transplantation (ASCT) and consolidating WBRT showed high remission rates [11, 12] . However, the applicability of intensive regimens is limited to younger patients. As the median age at diagnosis is 60-61 years [13, 14] , a substantial proportion of patients with PCNSL cannot be treated within intensive but curative regimens. Surviving patients are at substantial risk of developing leukoencephalopathy with dementia, ataxia, gait disturbances, and incontinence [15] . Particularly those >60 years are prone to this severe neurological complication and, consequently, those who survive have a very poor quality of life. In one study, 100% of patients >60 years who underwent chemoradiotherapy developed clinical neurotoxicity [3] . The main risk factors for leukoencephalopathy are radiotherapy, age >60 years, intrathecal therapy, and chemotherapy after WBRT [3, [15] [16] [17] . Taking into account the high risk of neurotoxicity after radiochemotherapy, we developed an MTX-based treatment protocol combined with oral alkylating agents for patients older than 65 years, omitting intrathecal chemotherapy and restricting WBRT to patients not responding to chemotherapy.
patients and methods eligibility criteria
Eligible for enrolments were immunocompetent patients with untreated PCNSL or intraocular lymphoma (IOL) >65 years (n = 27) or those below the age of 65 (n = 3) otherwise unfit for our simultaneously initiated highdose chemotherapy protocol with ASCT [12] have a neuropathological diagnosis of PCNSL (n = 29) or IOL (n = 1) on the basis of stereotactic (n = 29) or retinal biopsy (n = 1), respectively. Exclusion criteria were HIV seropositivity, systemic lymphoma manifestation, inadequate bone marrow function (defined as neutrophils <2 · 10 9 /l, platelets <100 · 10 9 /l), heart or kidney failure, and severe noncompensated pulmonary or liver disease. There was no minimum Karnofsky performance status limit. The study protocol was approved by the participating centres' local ethics committees. Patients were treated in accordance with the ethical standards of the Helsinki Declaration. This trial was initially conducted as a pilot study and continued as phase II trial. Inclusion and exclusion criteria did not differ between the pilot and study groups. Prior treatment with steroids was allowed and tapered once study treatment had begun.
staging before study inclusion
Pretreatment evaluation included contrast-enhanced magnetic resonance imaging (MRI) of the brain. Systemic non-Hodgkin's lymphoma was ruled out by CT scans of the chest and abdomen and unilateral bone marrow puncture with histologic, cytologic, and immunocytologic examination. Routine laboratory testing, creatinine clearance, echocardiography, and pulmonary function tests were carried out to exclude organ dysfunction as recommended [18] . We only carried out lumbar puncture and examined the cerebrospinal fluid (CSF) and eyes (slit lamp) when we suspected meningeal or ocular involvement. [18] . Complete remission (CR) was defined as the disappearance of all contrast enhancements in MRI in the absence of corticosteroids. Partial remission (PR) was defined as a ‡50% reduction in tumour size compared with the baseline MRI. PD was defined as ‡25% increase in tumour size or appearance of any new lesion. All other situations were considered as SD. Treatment toxicity was graded according to the Common Toxicity Criteria (CTC, version 3.0).
study design and treatment protocol

statistics
All patients enrolled (n = 30) were included in the analysis according to the intention-to-treat principle. End points of the study were OS and progression-free survival (PFS). OS was defined as time from initial diagnosis until death from any cause, and PFS was defined as time from diagnosis to disease progression or death due to any cause. Patients who did not experience the event of interest with respect to OS or PFS were considered as censored observations with time from first diagnosis to last follow-up visit as the censoring time. Response duration was defined for patients in CR as the time from first observation of response to the first time of progression or death and was censored at the time of last follow-up if the patient had not progressed or died. The Kaplan-Meier method was used to estimate survival probabilities and response duration probabilities with 95% confidence intervals (CIs). Median follow-up was determined for all patients. Survival probabilities were compared using the log-rank test and estimated hazard ratios with accompanying 95% CIs derived from a Cox proportional hazards regression model. Calculations were carried out using SAS software, version 9 (SAS Institute Inc. Figure 2 .
First cycle. Seventeen patients completed the first cycle and proceeded to the second cycle MCP, and 13 patients did not, due to intracranial thrombocytopenic bleeding (n = 1), hypertension and aortic aneurysm rupture (n = 1), asymptomatic liver toxicity [c-glutamyltransferase (GGT) elevation grade 3, n = 1; alanine aminotranferase (ALT) elevation grade 3, n = 1], renal insufficiency (grade unknown, n = 1), haematopoietic insufficiency (grade 3, n = 1; grade 4, n = 2), PD (n = 4), and refusal to proceed with therapy (n = 1).
Second cycle. Nine patients completed the second cycle and proceeded to the third cycle; reasons for discontinuing the protocol (n = 8) were creatinine elevation grade 3 (n = 1), acute lethal heart failure (n = 1), enteritis grade 3 (n = 1), haematopoietic insufficiency grade 3 (n = 1), PD (n = 3), and relapse from CR (n = 1).
response to therapy
Evaluation of response by contrast-enhanced MRI was carried out after two applications of MTX within the first cycle, before the third cycle, and at the end of therapy. Measurable lesions could be detected in 29 of 30 patients; in three patients response could not be evaluated due to unexpected death (n = 2) and immediate proceeding to WBRT (n = 1), respectively. Response data are depicted in detail in Figure 2 .
Overall objective response from chemotherapy (PR and CR) was seen in 19 of 27 (70.4%) assessable patients, 12 of 27 (44.4%) patients had a complete response and 7 of 27 (25.9%) achieved a partial response after study treatment.
follow-up
Eight of 30 (26.7%) patients are alive after a median follow-up of 78 months (range 34-105 months). The median OS and PFS are 15.4 months (95% CI 7.6-65.1) and 5.9 months (95% CI 2.7-26.6), respectively ( Figure 3) . The intention-to-treat analysis for all 30 patients revealed survival rates of 33.3% (95% CI 16.5-50.2) at both 3 and 5 years. One patient having achieved CR after one cycle MCP died from intracranial bleeding without cerebral lymphoma manifestation after 64 months, possibly as a late complication of therapy. After achieving CR, 5 of 14 patients relapsed after 7, 12, 13, 26, or 65 months. Two patients refused further treatment and three patients received salvage therapy for recurrent PCNSL. Of those, one underwent WBRT alone, one WBRT combined with procarbazine and CCNU; both patients died after 2 and 3 months, respectively. Another patient developed continuous CR after rituximab monotherapy as salvage treatment. When CR was attained from chemotherapy with (n = 2) or without WBRT (n = 12), the median response duration was 63.6 months.
According to the MSKCC PCNSL RPA classification, 13 patients fell into class 2 (intermediate risk, KPS ‡70%) and 17 patients into class 3 (poor prognostic group, KPS <70%). Fiveyear OS probability of patients in classes 2 and 3 were 38.5% (95% CI 12.0% to 64.9%) and 29.4% (95% CI 7.8% to 51.1%), respectively ( Figure 4) . Univariate Cox regression analysis for KPS ‡/< 70% showed no significant effect on OS (hazard ratio = 1.3, 95% CI 0.541-3.101, P 0.56).
acute toxicity
Toxicity data were available for 28 of 30 patients, with two patients dying early due to PD, thus leading to incomplete data. Chemotherapy was generally well tolerated. Leucopenia and thrombocytopaenia were the most frequent toxic effects. Grades 3 and 4 neutropenia, thrombocytopaenia, and anaemia were observed in 18 patients (64%), eight patients (29%), and nine patients (32%), respectively. Other grade 3 toxic effects included transient ALT and GGT elevation without liver dysfunction (2 of 28) and infections during neutropenia (8 of 28). Mild renal dysfunction (grades 1 and 2) was observed in five patients. Two unexpected nonlymphoma-associated, probably treatment-related deaths occurred during the course of study with one patient dying 20 days after initial treatment from thrombocytopenic cerebral haemorrhage, and the second patient died from cardiac failure during therapy. One further 
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patient died from a ruptured aortic aneurysm which was probably not treatment related. Of the eight surviving patients, two were irradiated due to intolerance of methotrexate. While we did not assess neurotoxicity via serial neurocognitive function testing, six of eight surviving, nonirradiated patients are in excellent (n = 3, KPS 100), good (n = 2, KPS 90), and moderate (n = 1, KPS 60) general condition; cognitive evaluation revealed no clinical signs of severe leukoencephalopathy (Mini-mental state examination 27, 28, 29, 30, 2 not evaluable). Two long-term surviving patients who required WBRT because of MTX toxicity suffer from dementia and gait disturbances due to progressive leukoencephalopathy-one of them with hemiparesis after ischaemic stroke.
discussion
This pilot and phase II study was conducted to assess the efficacy of a high-dose MTX-based chemotherapy protocol in older patients with PCNSL not qualifying for more intensive regimens. All drugs chosen in this protocol can penetrate the intact blood-brain barrier and are commonly used in the treatment of lymphoma. MTX is recognised as the single most effective cytostatic agent in the treatment of PCNSL when doses >1.5 g/m 2 are applied [3, 4, 8, [19] [20] [21] [22] Compared with other PCNSL treatment regimens [7, 12, 23, 24] , our MTX dose Figure 2 . Course of therapy, response, and outcome. m, male; f, female; BM, bone marrow, Crea, Creatinine; mo, months; CT, chemotherapy; AraC, cytarabine; MTX, methotrexate; CP, CCNU/Procarbazine; CR, complete remission; PR, partial remission; SD, stable disease; WBRT, whole-brain radiotherapy; PD, progressive disease; n.e., not evaluable. 2 is relatively low, in consideration of the patients' age and their age-related renal vulnerability. The orally applied agents procarbazine and lomustine are widely used in treating CNS neoplasms, due to their ability to pass the blood-brain barrier, as in the PCV-regimen [25] .
MTX monotherapy in patients with PCSNL has lead to 35%-90% remission rates in trials without age restrictions [6, 10, 21, [26] [27] [28] . The median PFS rates of trials with [21, 26] and without [6, [27] [28] [29] WBRT vary greatly with 32-40 months and 10-17 months, respectively. In contrast, their median OS times have a much narrower range, with 33 months in the two regimens containing WBRT and between 22.8 and 55.4 months in those without WBRT. Assuming that WBRT is the salvage therapy of choice in relapsed elderly patients not having received prior WBRT, these data suggest that the benefit of WBRT in terms of OS does not depend on whether it is administered as first-line or salvage treatment. There is still no generally accepted, standard WBRT dose for this indication.
Few trials have been carried out on the treatment of (exclusively) elderly patients with PCNSL. Subgroup analyses for patients >70 years in those trials that did not exclude older patients are discouraging, with reported median OS rates of 3-7 months with combined modality treatment regimens [30, 31] . In one trial with a therapy regimen similar to the one we present in this paper, MTX 1 g/m 2 was combined with procarbazine, CCNU, methylprednisolone, and intrathecal therapy with MTX and AraC in patients older than 60 years [32] . The objective response rate (CR and PR) was 48%. After a relatively short median follow-up of 3 years, median survival was 14.3 months. The rate of neurotoxicity was moderate, with a decline in Mini-Mental State Examination scores in three patients and late neurotoxicity in one of 14 long-term responders. Other prospective trials using high-dose MTXbased chemotherapy without WBRT in patients older than 60 years reported median survival rates of 14.3-34 months [4, 7, 22, 32, 33] . Due to our study's lower 65-year age limit, our results fall between the reports of patients older than 60 years and those >70 years.
Our trial's median OS is relatively short; however, this may well be due to the patients' low initial median KPS of 60% and their numerous comorbidities. Furthermore, the threshold for stopping chemotherapy in patients who showed moderate side-effects was initially low, and they were taken off study (intention-to-treat). This factor is reflected in the early drop in the survival curve (Figure 3) . The 5-year OS of 33% is encouraging, considering our patients' poor prognostic factors; 17 of 30 included patients (53%) had a KPS <70% at initial diagnosis and fall into class 3 (poor prognostic group) regarding the MSKCC PCNSL RPA classification [13] . Of the eight long-term survivors, five were defined as class 2, and three as class 3 patients, even though subgroup analysis showed no significant difference. Only one had to be salvaged, three further patients received WBRT due to intolerance of methotrexate.
Considering our long median follow-up of 78 months, we conclude that 30% long-term remissions are achievable with MTX-based polychemotherapy and WBRT limited exclusively to nonresponders. Two of 30 patients with PR and intolerance of methotrexate received successful consolidating WBRT leading to ongoing CR for 36+ and 90+ months, both patients suffer from dementia and gait disturbances following WBRT with 36 and 40 Gy. There is still controversy about the significance of consolidating radiotherapy after methotrexatebased chemotherapy. WBRT doses of 40-50 Gy can lead to severe neurotoxicity, particularly in patients >60 years [3] . Promising results for reduced consolidating WBRT of 23.4 Gy were recently reported [34] . On the other hand, two of our patients showed disease control after one and two cycles of 64 and 36+ months, respectively. This observation reflects that a subset of elderly patients has an extremely methotrexatesensitive PCNSL and are probably unnecessarily overtreated with WBRT alone. This is worrying since a current population-based analysis [35] demonstrates that radiotherapy is the most common treatment modality for older patients with PCNSL. Despite the common perception that high-dose methotrexate is too toxic for older patients, our data show that older patients can tolerate high-dose MTX with acceptable renal toxicity, confirming the observation of others [24, 36] .
Clinical signs of leukoencephalopathy after successful PCNSL treatment usually include rapidly progressive dementia, followed by gait disturbances and incontinence [15] . Lymphoma-associated and therapy-associated neurocognitive deficits are frequently indistinguishable, especially in patients presenting with dementia as the initial PCNSL symptom. Furthermore, signs of leukoencephalopathy in MRT (such as white matter lesions) do not necessarily correlate with the degree of clinical deficits. Leukoencephalopathy and treatment-related cognitive impairment are often only distinguishable by the deficits' chronology. Because patients >60 years are highly vulnerable to treatment-related neurotoxicity with rates of leukoencephalopathy of up to 100% [3] reported, we restricted WBRT to patients not responding to chemotherapy in our trial. Of the eight long-term survivors in our trial, two were irradiated because of MTX toxicity, preventing further application of that drug. Both patients have suffered from slowly progressive dementia since WBRT. Of the other surviving patients, five are doing well with practically unimpaired everyday performance status. Considering the poor quality of life in patients suffering from progressive leukoencephalopathy, we suggest that the designation 'leukoencephalopathy-free survival' should be discussed as a suitable parameter of outcome for patients with PCNSL.
What can be considered the best treatment regimen for older patients with PCNSL remains controversial. Despite the recommendation to avoid WBRT in older patients aged ‡60 years, the majority of elderly PCNSL patients are offered treatment with WBRT alone, resulting in poor survival rates of 7.6 months [1, 35] . The elderly patient population is relatively understudied and appropriate clinical trials are few and far between. Our experience and that of others [5, 24, 32, 36] demonstrate that high-dose MTX is well tolerated in older patients, provided their renal function is adequate. We maintain that WBRT treatment should be restricted to refractory disease, considering the radiation-vulnerable brains in the elderly and the resulting quality-of-life impairment. The addition of procarbazine and CCNU (as lymphoma-toxic cytostatic agents penetrating the blood-brain barrier) to highdose MTX may improve remission and survival rates, but the increased haematological toxicity is worrying, demanding great caution when given to older patients.
In conclusion, with its long-term follow-up, our study demonstrates that a proportion of elderly patients with PCNSL can be cured with MTX-based chemotherapy in the absence of obligatory consolidating radiotherapy, leading to a low rate of leukoencephalopathy and consequently high quality of life of surviving patients. A subsequent phase II trial with MCP and additional rituximab in older patients may further increase response rates and OS without compromising treatment tolerability.
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